Aachen, Germany, 06 July 2021 – Grünenthal, a science-based pharmaceutical company and a leader in pain therapy, announced today that it has launched an offering (the “Offering”) of €300,000,000 aggregate principal amount of additional senior secured notes.
The notes will be issued under the existing indenture dated May 5, 2021, pursuant to which Grünenthal GmbH issued its existing €400,000,000 senior secured notes due 2026 and €250,000,000 senior secured notes due 2028. The proceeds from the Offering, if completed, will be used, together with cash on hand, to repay existing indebtedness and pay costs, fees and expenses related to the Offering.
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in around 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn.
More information: www.creditors.grunenthal.com
Follow us on:
- LinkedIn: Grunenthal Group
- Instagram: grunenthal
Head Global Communication